Reduction in basal nitric oxide activity causes albuminuria

Diabetes

Volumn 60, Issue 2, 2011, Pages 572-576

  Ott, Christian ^a   Schneider, Markus P ^a   Delles, Christian ^b   Schlaich, Markus P ^c   Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE;

ADULT; ALBUMIN URINE LEVEL; ALBUMINURIA; ARTICLE; CREATININE URINE LEVEL; ENZYME INHIBITION; EPITHELIUM BASAL CELL; FEMALE; GLOMERULAR DYSFUNCTION; GLOMERULUS EPITHELIUM; GLOMERULUS FILTRATION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY FUNCTION; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION RESEARCH; PRIORITY JOURNAL; URINE LEVEL;

AGED; ALBUMINS; ALBUMINURIA; BLOOD PRESSURE; CREATININE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OMEGA-N-METHYLARGININE; REGRESSION ANALYSIS;

EID: 79551582074     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db09-1630     Document Type: Article

References (37)

1. Kannel WB, Stampfer MJ, Castelli WP, Verter J. The prognostic significance of proteinuria: the Framingham study. Am Heart J 1984;108:1347-1352
2. Samuelsson O, Wilhelmsen L, Elmfeldt D, Pennert K, Wedel H, Wikstrand J, Berglund G. Predictors of cardiovascular morbidity in treated hypertension: results from the primary preventive trial in Göteborg, Sweden. J Hypertens 1985;3:167-176
3. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, Marcantoni C, de Jong PE, de Zeeuw D, Shahinfar S, Ruggenenti P, Remuzzi G, Levey AS, the AIPRD Study Group. Angiotensin-Converting Enzymne Inhibition and Progression of Renal Disease. Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney Int 2001;60:1131-1140
4. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen WM, Grobbee DE, de Jong PE, the Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002;106:1777-1782
5. Schmitz A, Vaeth M. Microalbuminuria: a major risk factor in non-insulin-dependent diabetes. A 10-year follow-up study of 503 patients. Diabet Med 1988;5:126-134
6. Savage S, Nagel NJ, Estacio RO, Lukken N, Schrier RW. Clinical factors associated with urinary albumin excretion in type II diabetes. Am J Kidney Dis 1995;25:836-844
7. Gerstein HC, Mann JF, Pogue J, Dinneen SF, Hallé JP, Hoogwerf B, Joyce C, Rashkow A, Young J, Zinman B, Yusuf S. Prevalence and determinants of microalbuminuria in high-risk diabetic and nondiabetic patients in the Heart Outcomes Prevention Evaluation Study: the HOPE Study Investigators. Diabetes Care 2000;23(Suppl. 2):B35-B39
8. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V, Rubis N, Gherardi G, Arnoldi F, Ganeva M, Ene-Iordache B, Gaspari F, Perna A, Bossi A, Trevisan R, Dodesini AR, Remuzzi G, the Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-1951
9. Hillege HL, Janssen WM, Bak AA, Diercks GF, Grobbee DE, Crijns HJ, Van Gilst WH, De Zeeuw D, De Jong PE, the Prevend Study Group. Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity. J Intern Med 2001;249:519-526 (Pubitemid 32823860)
10. Garg AX, Kiberd BA, Clark WF, Haynes RB, Clase CM. Albuminuria and renal insufficiency prevalence guides population screening: results from the NHANES III. Kidney Int 2002;61:2165-2175
11. Romundstad S, Holmen J, Kvenild K, Aakervik O, Hallan H. Clinical relevance of microalbuminuria screening in self-reported non-diabetic/ nonhypertensive persons identified in a large health screening: the Nord-Trøndelag Health Study (HUNT), Norway. Clin Nephrol 2003;59:241-251
12. Atkins RC, Polkinghorne KR, Briganti EM, Shaw JE, Zimmet PZ, Chadban SJ. Prevalence of albuminuria in Australia: the AusDiab Kidney Study. Kidney Int Suppl 2004;66(Suppl. 92s):S22-S24
13. Smithies O. Why the kidney glomerulus does not clog: a gel permeation/diffusion hypothesis of renal function. Proc Natl Acad Sci USA 2003;100:4108-4113
14. Ballermann BJ, Stan RV. Resolved: capillary endothelium is a major contributor to the glomerular filtration barrier. J Am Soc Nephrol 2007;18:2432-2438
15. Comper WD, Haraldsson B, Deen WM. Resolved: normal glomeruli filter nephrotic levels of albumin. J Am Soc Nephrol 2008;19:427-432
16. Ballermann BJ. Contribution of the endothelium to the glomerular permselectivity barrier in health and disease. Nephron Physiol 2007;106:19-25
17. Govers R, Rabelink TJ. Cellular regulation of endothelial nitric oxide synthase. Am J Physiol Renal Physiol 2001;280:F193-F206
18. Wolfrum S, Jensen KS, Liao JK. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003;23:729-736
19. Stehouwer CD. Endothelial dysfunction in diabetic nephropathy: state of the art and potential significance for non-diabetic renal disease. Nephrol Dial Transplant 2004;19:778-781
20. Schäufele TG, Schlaich MP, Delles C, Klingbeil AU, Fleischmann EH, Schmieder RE. Impaired basal NO activity in patients with glomerular disease and the influence of oxidative stress. Kidney Int 2006;70:1177-1181
21. Mohan S, Reddick RL, Musi N, Horn DA, Yan B, Prihoda TJ, Natarajan M, Abboud-Werner SL. Diabetic eNOS knockout mice develop distinct macro- and microvascular complications. Lab Invest 2008;88:515-528 (Pubitemid 351581457)
22. Zanchi A, Moczulski DK, Hanna LS, Wantman M, Warram JH, Krolewski AS. Risk of advanced diabetic nephropathy in type 1 diabetes is associated with endothelial nitric oxide synthase gene polymorphism. Kidney Int 2000;57:405-413
23. Shin Shin Y, Baek SH, Chang KY, Park CW, Yang CW, Jin DC, Kim YS, Chang YS, Bang BK. Relations between eNOS Glu298Asp polymorphism and progression of diabetic nephropathy. Diabetes Res Clin Pract 2004;65:257-265
24. Schmieder RE, Veelken R, Schobel H, Dominiak P, Mann JF, Luft FC. Glomerular hyperfiltration during sympathetic nervous system activation in early essential hypertension. J Am Soc Nephrol 1997;8:893-900
25. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage: the Steno hypothesis. Diabetologia 1989;32:219-226
26. Feldt-Rasmussen B. Increased transcapillary escape rate of albumin in type 1 (insulin-dependent) diabetic patients with microalbuminuria. Diabetologia 1986;29:282-286
27. Nannipieri M, Rizzo L, Rapuano A, Pilo A, Penno G, Navalesi R. Increased transcapillary escape rate of albumin in microalbuminuric type II diabetic patients. Diabetes Care 1995;18:1-9
28. Nosadini R, Velussi M, Brocco E, Abaterusso C, Piarulli F, Morgia G, Satta A, Faedda R, Abhyankar A, Luthman H, Tonolo G. Altered transcapillary escape of albumin and microalbuminuria reflects two different pathogenetic mechanisms. Diabetes 2005;54:228-233
29. Jensen JS, Borch-Johnsen K, Jensen G, Feldt-Rasmussen B. Microalbuminuria reflects a generalized transvascular albumin leakiness in clinically healthy subjects. Clin Sci (Lond) 1995;88:629-633
30. Kanetsuna Y, Takahashi K, Nagata M, Gannon MA, Breyer MD, Harris RC, Takahashi T. Deficiency of endothelial nitric-oxide synthase confers susceptibility to diabetic nephropathy in nephropathy-resistant inbred mice. Am J Pathol 2007;170:1473-1484
31. Sharma M, McCarthy ET, Savin VJ, Lianos EA. Nitric oxide preserves the glomerular protein permeability barrier by antagonizing superoxide. Kidney Int 2005;68:2735-2744
32. Datta PK, Sharma M, Duann P, Lianos EA. Effect of nitric oxide synthase inhibition on proteinuria in glomerular immune injury. Exp Biol Med (Maywood) 2006;231:576-584
33. Giner V, Tormos C, Chaves FJ, Sáez G, Redón J. Microalbuminuria and oxidative stress in essential hypertension. J Intern Med 2004;255:588-594
34. Ozdemir G, Ozden M, Maral H, Kuskay S, Cetinalp P, Tarkun I. Malondialdehyde, glutathione, glutathione peroxidase and homocysteine levels in type 2 diabetic patients with and without microalbuminuria. Ann Clin Biochem 2005;42:99-104
35. Makino H, Doi K, Hiuge A, Nagumo A, Okada S, Miyamoto Y, Suzuki M, Yoshimasa Y. Impaired flow-mediated vasodilatation and insulin resistance in type 2 diabetic patients with albuminuria. Diabetes Res Clin Pract 2008;79:177-182
36. Stehouwer CD, Henry RM, Dekker JM, Nijpels G, Heine RJ, Bouter LM. Microalbuminuria is associated with impaired brachial artery, flow-mediated vasodilation in elderly individuals without and with diabetes: further evidence for a link between microalbuminuria and endothelial dysfunction: the Hoorn Study. Kidney Int Suppl 2004;66(Suppl. 92s):S42-S44
37. Schmieder RE, Schrader J, Zidek W, Tebbe U, Paar WD, Bramlage P, Pittrow D, Böhm M. Low-grade albuminuria and cardiovascular risk: what is the evidence? Clin Res Cardiol 2007;96:247-257